Impact of different exercise training modalities on the coronary collateral circulation and plaque composition in patients with significant coronary artery disease (EXCITE trial): study protocol for a randomized controlled trial

Trials

Sven Möbius-Winkler¹  Gerhard C Schuler¹  Martin Grunze⁴  Matthias Gutberlet²  Thomas Hilberg³  Holger Thiele¹  Jennifer Adam¹  Sandra Erbs¹  Axel Linke¹  Karsten Lenk¹  Volker Adams¹  Madlen Uhlemann¹ 

[1] Department of Internal Medicine/Cardiology, Heart Centre, University of Leipzig, Strümpellstrasse 39, Leipzig, 04289, Germany;Department for Radiology, Heart Centre, University of Leipzig, Leipzig, Germany;Sports medicine, University Wuppertal, Wuppertal, Germany;MediClin-Klinikum Trassenheide, Trassenheide, Germany

关键词: Pathophysiology;    Interval training;    Exercise training;    Collateral circulation;    Coronary collateral blood flow;    Coronary artery disease;    Atherogenesis;   

Others  :  1095338
DOI  :  10.1186/1745-6215-13-167

 received in 2012-04-01, accepted in 2012-07-18,  发布年份 2012

【 摘 要 】

Background

Exercise training (ET) in addition to optimal medical therapy (OMT) in patients with stable coronary artery disease (CAD) has been demonstrated to be superior to percutaneous coronary interventions (PCI) with respect to the composite endpoint of death, myocardial infarction, stroke, revascularization and hospitalization due to worsening of angina. One mechanism leading to this superiority discussed in the literature is the increase in coronary collateral blood flow due to ET. Until now, data demonstrating the positive effect of ET on the collateral blood flow and the functional capacity of the coronary collateral circulation are still lacking.

Methods/design

The EXCITE trial is a three-armed randomized, prospective, single-center, open-label, controlled study enrolling 60 patients with stable CAD and at least one significant coronary stenosis (fractional flow reserve ≤0.75). The study is designed to compare the influence and efficacy of two different 4-week ET programs [high-intensity interval trainings (IT) versus moderate-intensity exercise training (MT) in addition to OMT] versus OMT only on collateral blood flow (CBF). The primary efficacy endpoint is the change of the CBF of the target vessel after 4 weeks as assessed by coronary catheterization with a pressure wire during interruption of the antegrade flow of the target vessel by balloon occlusion. Secondary endpoints include the change in plaque composition as assessed by intravascular ultrasound (IVUS) after 4 weeks, myocardial perfusion as analyzed in MRI after 4 weeks and 12 months, peak oxygen uptake (V02 peak), change in endothelial function and biomarkers after 4 weeks, 3, 6 and 12 months. The safety endpoint addresses major adverse cardiovascular events (death from cardiovascular cause, myocardial infarction, stroke, TIA, target vessel revascularization or hospitalization) after 12 months.

Discussion

The trial investigates whether ET for 4 weeks increases the CBF in patients with significant CAD compared to a sedentary control group. It also examines the impact of two intensities of ET on the CBF as well as the histological plaque composition. The trial started recruitment in June 2009 and will complete recruitment until June 2012. First results are expected in December 2012 (4-week follow-up), final results (12-month long-term secondary endpoint) in December 2013.

Trial registration

Clinical trial registration information-URL: http://www.clinicaltrials.gov webcite.

Unique identifier: NCT01209637

【 授权许可】

   
2012 Uhlemann et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Landmesser U, Hornig B, Drexler H: Endothelial function: a critical determinant in atherosclerosis? Circulation 2004, 109:II27-II33.
• [2]Libby P, Aikawa M, Jain MK: Vascular endothelium and atherosclerosis. Handb Exp Pharmacol 2006, 176:285-306.
• [3]Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al.: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001, 344:1879-1887.
• [4]Lagerqvist B, Husted S, Kontny F, Stshle E, Swahn E, Wallentin L: 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. Lancet 2006, 368:998-1004.
• [5]Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al.: Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007, 356:1503-1516.
• [6]Boden WE, O’Rourke RA, Teo KK, Maron DJ, Hartigan PM, Sedlis SP, et al.: Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE trial). Am J Cardiol 2009, 104:1-4.
• [7]Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, et al.: A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009, 360:2503-2515.
• [8]Sedlis SP, Jurkovitz CT, Hartigan PM, Goldfarb DS, Lorin JD, Dada M, et al.: Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease. Am J Cardiol 2009, 104:1647-1653.
• [9]Teo KK, Sedlis SP, Boden WE, O’Rourke RA, Maron DJ, Hartigan PM, et al.: Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (clinical outcomes utilizing revascularization and aggressive drug evaluation) trial. J Am Coll Cardiol 2009, 54:1303-1308.
• [10]Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkovitz C, et al.: Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med 2008, 359:677-687.
• [11]Ahmed B, Dauerman HL, Piper WD, Robb JF, Verlee MP, Ryan TJ, et al.: Recent changes in practice of elective percutaneous coronary intervention for stable angina. Circ Cardiovasc Qual Outcomes 2011, 4:300-305.
• [12]Atwater BD, Oujiri J, Wolff MR: The immediate impact of the clinical outcomes utilizing revascularization and aggressive grug evaluation (COURAGE) trial on the management of stable angina. Clin Cardiol 2009, 32:E1-E3.
• [13]Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al.: Optimal medical therapy with or without PCI for stable coronary disease. N Eng J Med 2007, 356:1503-1516.
• [14]Maron D, Boden W, Weintraub W, Calfas K, OGÇÖRourke R: Is optimal medical therapy as used in the COURAGE trial feasible for widespread use? Current Treatment Options in Cardiovascular Medicine 2011, 13:16-25.
• [15]Maron DJ, Boden WE, O’Rourke RA, Hartigan PM, Calfas KJ, Mancini GBJ, et al.: Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (clinical outcomes utilizing revascularization and aggressive drug evaluation) trial. J Am Coll Cardiol 2010, 55:1348-1358.
• [16]Maron DJ, Boden WE, Spertus JA, Hartigan PM, Mancini GBJ, Sedlis SP, et al.: Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (clinical outcomes utilizing revascularization and aggressive drug evaluation) trial. J Am Coll Cardiol 2011, 58:131-137.
• [17]Schömig A, Mehilli J, de Waha A, Seyfarth M, Pache J, Kastrati A: A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease. J Am Coll Cardiol 2008, 52:894-904.
• [18]Blumgart HL, Freedberg AS: The effect of dicumarol on the heart in experimental acute coronary occlusion. Am Heart J 1948, 36:13-27.
• [19]Gregg DE, Patterson RE: Functional importance of the coronary collaterals. N Engl J Med 1980, 303:1404-1406.
• [20]Balachandran KP, Berry C, Pell AC, Vance BD, Oldroyd KG: Improvement in left ventricular function following successful rescue percutaneous coronary intervention is independent of time-to-reperfusion. J Invasive Cardiol 2006, 18:330-333.
• [21]Seiler C: The human coronary collateral circulation. Eur J Clin Invest 2010, 40:465-476.
• [22]Desch S, Eitel I, Schmitt J, Sareban M, Fuernau G, Schuler G, et al.: Effect of coronary collaterals on microvascular obstruction as assessed by magnetic resonance imaging in patients with acute st-elevation myocardial infarction treated by primary coronary intervention. Am J Cardiol 2009, 104:1204-1209.
• [23]Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko HR, et al.: Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The stanford coronary risk intervention project (SCRIP). Circulation 1994, 89:975-990.
• [24]Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, et al.: Intensive lifestyle changes for reversal of coronary heart disease. JAMA 1998, 280:2001-2007.
• [25]Kokkinos P, Myers J, Kokkinos JP, Pittaras A, Narayan P, Manolis A, et al.: Exercise capacity and mortality in black and white men. Circulation 2008, 117:614-622.
• [26]Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE: Exercise capacity and mortality among men referred for exercise testing. N Eng J Med 2002, 346:793-801.
• [27]Hambrecht R, Walther C, Mobius-Winkler S, Gielen S, Linke A, Conradi K, et al.: Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation 2004, 109:1371-1378.
• [28]Hambrecht R, Wolf A, Gielen S, Linke A, Hofer J, Erbs S, et al.: Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Eng J Med 2000, 342:454-460.
• [29]Cornish AK, Broadbent S, Cheema BS: Interval training for patients with coronary artery disease: a systematic review. Eur J Appl Physiol 2011, 111:579-589.
• [30]Hambrecht R, Niebauer J, Marburger C, Grunze M, K + ñlberer B, Hauer K, et al.: Various intensities of leisure time physical activity in patients with coronary artery disease: effects on cardiorespiratory fitness and progression of coronary atherosclerotic lesions. J Am Coll Cardiol 1993, 22:468-477.
• [31]Wilkins DT, Helfant RH, Vokonas PS, Gorlin R: Coronary collateral circulation. N Engl J Med 1971, 285:352-353.
• [32]Helfant RH, Vokonas PS, Gorlin R: Functional importance of the human coronary collateral circulation. N Engl J Med 1971, 284:1277-1281.
• [33]Niebauer J, Hambrecht R, Marburger C, Hauer K, Velich T, von Hodenberg E: Impact of intensive physical exercise and low-fat diet on collateral vessel formation in stable angina pectoris and angiographically confirmed coronary artery disease. Am J Cardiol 1995, 76:771-775.
• [34]Pijls NH, Van GB, Van der Voort P, Peels K, Bracke FA, Bonnier HJ, et al.: Fractional flow reserve. A useful index to evaluate the influence of an epicardial coronary stenosis on myocardial blood flow. Circulation 1995, 92:3183-3193.
• [35]Pijls NHJ, Willem Bech GJ, El Gamal MIH, Bonnier HJRM, De Bruyne B, Van Gelder B, et al.: Quantification of recruitable coronary collateral blood flow in conscious humans and its potential to predict future ischemic events. J Am Coll Cardiol 1995, 25:1522-1528.
• [36]Cohen MV, Yipintsoi T, Malhotra A, Penpargkul S, Scheuer J: Effect of exercise on collateral development in dogs with normal coronary arteries. J Appl Physiol 1978, 45:797-805.
• [37]Scheel KW, Ingram LA, Wilson JL: Effects of exercise on the coronary and collateral vasculature of beagles with and without coronary occlusion. Circ Res 1981, 48:523-530.
• [38]Zbinden R, Zbinden S, Meier P, Hutter D, Billinger M, Wahl A, et al.: Coronary collateral flow in response to endurance exercise training. Eur J Cardiovasc Prev Rehabil 2007, 14:250-257.
• [39]Sandri M, Adams V, Gielen S, Linke A, Lenk K, Kr + ñnkel N: Effects of exercise and ischemia on mobilization and functional activation of blood-derived progenitor cells in patients with ischemic syndromes. Circulation 2005, 111:3391-3399.
• [40]Buschmann EE, Utz W, Pagonas N, Schulz-Menger J, Busjahn A, Monti J, et al.: Improvement of fractional flow reserve and collateral flow by treatment with external counterpulsation (Art.Net.-2 Trial). Eur J Clin Invest 2009, 39:866-875.
• [41]Meier P, Hemingway H, Lansky AJ, Knapp G, Pitt B, Seiler C: The impact of the coronary collateral circulation on mortality: a meta-analysis. Eur Heart J 2012, 33:614-621.
• [42]Meier P, Gloekler S, Zbinden R, Beckh S, de Marchi SF, Zbinden S, et al.: Beneficial effect of recruitable collaterals. Circulation 2007, 116:975-983.
• [43]Pohl T, Wustmann K, Zbinden S, Windecker S, Mehta H, Meier B, et al.: Exercise-induced human coronary collateral function: quantitative assessment during acute coronary occlusions. Cardiology 2003, 100:53-60.
• [44]Wustmann K, Zbinden S, Windecker S, Meier B, Seiler C: Is there functional collateral flow during vascular occlusion in angiographically normal coronary arteries? Circulation 2003, 107:2213-2220.
• [45]Rao SV, O’Grady K, Pieper KS, Granger CB, Newby LK, Mahaffey KW, et al.: A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 2006, 47:809-816.
• [46]Fearon WF, Tonino PA, De Bruyne B, Siebert U, Pijls NH: Rationale and design of the fractional flow reserve versus angiography for multivessel evaluation (FAME) study. Am Heart J 2007, 154:632-636.
• [47]Pijls NH, Fearon WF, Tonino PA, Siebert U, Ikeno F, Bornschein B, et al.: Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (fractional flow reserve versus angiography for multivessel evaluation) study. J Am Coll Cardiol 2010, 56:177-184.
• [48]Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, Veer M, et al.: Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 2009, 360:213-224.
• [49]Nicholls SJ, Tuzcu EM, Kalidindi S, Wolski K, Moon KW, Sipahi I, et al.: Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol 2008, 52:255-262.
• [50]Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P, et al.: Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 2006, 354:1253-1263.
• [51]Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al.: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295:1556-1565.
• [52]Nissen SE, Nicholls SJ, Wolski K, Rodes-Cabau J, Cannon CP, Deanfield JE, et al.: Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008, 299:1547-1560.
• [53]Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al.: Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008, 299:1561-1573.
• [54]Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, et al.: American College of Cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001, 37:1478-1492.
• [55]Möbius-Winkler S, Hilberg T, Menzel K, Golla E, Burman A, Schuler G, et al.: Time-dependent mobilization of circulating progenitor cells during strenuous exercise in healthy individuals. J Appl Physiol 2009, 107:1943-1950.
• [56]Matsumoto Y, Adams V, Walther C, Kleinecke C, Brugger P, Linke A, et al.: Reduced number and function of endothelial progenitor cells in patients with aortic valve stenosis: a novel concept for valvular endothelial cell repair. Eur Heart J 2009, 30:346-355.